US HB7037 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on May 27 2020 - 25% progression, died in committee
Action: 2020-05-27 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on May 27 2020 - 25% progression, died in committee
Action: 2020-05-27 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
(1) establishes documentation requirements for testing, treatment, and reporting related to COVID-19 (i.e., coronavirus disease 2019); and (2) makes it unlawful to knowingly report a false diagnosis of COVID-19. To receive a federal reimbursement for the cost of a COVID-19 diagnostic test or treatment, the request for reimbursement must document that the administered COVID-19 test has been approved, cleared, or authorized by the Food and Drug Administration.Further, the Centers for Disease Control and Prevention must exclude from its official COVID-19 case and death counts any person who tested positive and requested federal reimbursement without the required documentation.Additionally, any person who knowingly reports a false diagnosis of COVID-19 is subject to criminal fines and imprisonment for not more than 10 years.
Title
To provide for quality assurance of COVID-19 reimbursements and reporting.
Sponsors
Rep. Bill Posey [R-FL] |
History
Date | Chamber | Action |
---|---|---|
2020-05-27 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2020-05-27 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2020-05-27 | House | Introduced in House |
Subjects
Cardiovascular and respiratory health
Drug safety, medical device, and laboratory regulation
Emergency medical services and trauma care
Fraud offenses and financial crimes
Health
Health care costs and insurance
Health care coverage and access
Health information and medical records
Health programs administration and funding
Infectious and parasitic diseases
Medical tests and diagnostic methods
Drug safety, medical device, and laboratory regulation
Emergency medical services and trauma care
Fraud offenses and financial crimes
Health
Health care costs and insurance
Health care coverage and access
Health information and medical records
Health programs administration and funding
Infectious and parasitic diseases
Medical tests and diagnostic methods
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/7037/all-info |
Text | https://www.congress.gov/116/bills/hr7037/BILLS-116hr7037ih.pdf |